Detalhe da pesquisa
1.
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
N Engl J Med
; 380(23): 2225-2236, 2019 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166681
2.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Blood
; 135(26): 2402-2412, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32206772
3.
Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
Am J Hematol
; 96(9): 1112-1119, 2021 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34050972
4.
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 21(9): 1188-1200, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32888452
5.
High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia.
Blood
; 135(11): 866-870, 2020 03 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31990291
6.
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
Adv Ther
; 39(8): 3635-3653, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35708885
7.
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study.
J Clin Oncol
; 39(36): 4049-4060, 2021 12 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34709929
8.
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
J Hematol Oncol
; 11(1): 122, 2018 09 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-30249277